Abstract: The current invention relates to novel platinum(II) based organometallic materials. These materials show high emission quantum efficiencies and low self-quenching constant. Also provided are high efficiency, green to orange emitting organic light-emitting diode (OLED) that are fabricated using platinum(II) based organometallic materials as the light-emitting material. The organometallic materials of the invention are soluble in common solvents; therefore, solution process methods such as spin coating and printing can be used for device fabrication. The devices fabricated from these materials show low efficiency roll-off.

Abstract: The present disclosure is related to a pharmaceutical composition for treatment of cancer comprising a cyclometalated N-heterocyclic carbene complex. The cyclometalated N-heterocyclic carbene complex contains a gold(III) or a platinum(II) atom. The pharmaceutical composition possesses anti-cancer activity such as the induction of cell death, inhibition of cellular proliferation, inhibition of topoisomerase and/or poisoning of topoisomerase.

Abstract: Subject matter disclosed herein relates to a series of palladium based materials, their preparation method and their applications in an organic light-emitting diode (OLED).

Abstract: The invention relates to nitridoosmium complexes and methods of using these compounds as treatments for cancer.

Abstract: The subject invention is directed to tetradentate bis-(NHC carbenes) alkylene ligand Pt(II) complexes, tetradentate bis-(NHC carbenes) alkylene ligands, and its ligand precursors, for preparation of the Pt(II) complexes. The Pt(II) complexes show a deep blue emission with an improved quantum efficiency and can be used for fabrication of OLEDs with an electroluminescence layer that comprise the bis-(NHC carbenes) alkylene ligand Pt(II) complexes.

Abstract: Described are novel platinum (II) containing organometallic materials. These materials show green to orange emissions with high emission quantum efficiencies. Using the materials as emitting materials; pure green emitting organic light-emitting diodes can be fabricated. Since the novel platinum (II) containing organometallic materials are soluble in common solvents, solution process methods such as spin coating and printing can be used for device fabrication.

Abstract: Solid-supported gold nanoparticles for use as a catalyst for the synthesis of quinolines from anilines and aldehydes using oxygen as an oxidant are provided. Also provided are a method for the preparation of SiO2-supported gold nanoparticles by in situ deposition of gold nanoparticles to silica gel and a method for synthesizing quinolines from anilines and aldehydes using oxygen as an oxidant.

Abstract: The present invention relates to metal thiourea complexes comprising N-substituted thiourea ligands and sulfur-coordinated metal ions, and methods for using the metal thiourea complexes for delivering otherwise unstable or impermeable metal ions to mammalian cells, for inhibiting cancer cell growth and inflammation, and for inhibiting the activities of associated drug targets under in vitro and in vivo conditions. The metal complexes of N-substituted thiourea are defined by the following formula (Ia or Ib) wherein R1 can be H, alkyl, alkenyl, alkynyl, aryl or heterocyclic groups; R2 can be H, alkyl, alkenyl, alkynyl or aryl groups; n=1 to 4; X? is a pharmaceutically acceptable anion (chloride, bromide, iodide, hexafluorophosphate, or triflate) and M is a coinage metal (Au, Ag, or Cu).

Abstract: The invention relates to nitridoosmium complexes and methods of using these compounds as treatments for cancer.

Abstract: Organic photovoltaic (OPV) cells and methods of forming the same are provided. An OPV cell can include an organic photoactive layer comprising bis-(8-quinolinolato-N,O)platinum (II) (PtQ2) having a general structure disclosed herein as Structure I. A method of forming an OPV cell can include forming an organic photoactive layer on a substrate, which can include a transparent electrode. The organic photoactive layer can comprises PtQ2 having the general structure of Structure I.

Abstract: The present disclosure is related to a pharmaceutical composition for treatment of cancer comprising a cyclometalated N-heterocyclic carbene complex. The cyclometalated N-heterocyclic carbene complex contains a gold(III) or a platinum(II) atom. The pharmaceutical composition possesses anti-cancer activity such as the induction of cell death, inhibition of cellular proliferation, inhibition of topoisomerase and/or poisoning of topoisomerase.

Abstract: A method for treatment of cancer by inhibiting the activity of histone deacetylase, comprising administering to a human in need of such treatment a composition containing a therapeutically effective amount of a gold(III) complex having the structural formula of or a pharmaceutically acceptable salt thereof, wherein: —R is selected from the group consisting of —OH, —CH2OH, C2H4OH, —C3H6OH or —C4H8OH; and X is independently a pharmaceutically acceptable counter-ion.

Abstract: Ruthenium nanoparticles supported on non-cross-linked soluble polystyrene were prepared by reacting [RuCl2(C6H5CO2Et)]2 with polystyrene in open air. They effectively catalyze intra- and intermolecular carbenoid insertion into C—H and N—H bonds, alkene cyclopropanation, and ammonium ylide/[2,3]-sigmatropic rearrangement reactions. This supported ruthenium catalyst is much more reactive than [RuCl2(p-cymene)]2 and Ru(Por)CO] for catalytic intermolecular carbenoid C—H bond insertion into saturated alkanes. By using a-diazoacetamide as a substrate for intramolecular carbenoid C—H insertion, the supported ruthenium catalyst can be to recovered and reused for ten successive iterations without significant loss of activity.

Abstract: This invention provides a class of organometallic complexes comprising a tridentate isoquinoline-pyridine-benzene based ligand, a mono-dentate ligand and a platinum (II) center which show high emission quantum efficiency and good thermal stability. This invention also discloses organometallic complexes in organic light-emitting diode (OLED) including them.

Abstract: Highly fluorescent metallo-supramolecules based on terpyridine-based monomers and transition metals have been obtained. These robust supramolecules provide high quantum yields with emissions from violet to blue, green or yellow color. They have emerged as promising emitters for polymeric light-emitting diodes (PLEDs) due to desirable properties such as high luminance, high purity, low cost, and good thermal stabilities.

Abstract: Disclosed herein are novel light-emitting materials of Formula I and II below. These new complexes are synthesized and found to be sufficiently stable to allow sublimation and vacuum deposition. These new emitters are electrophosphorescent and can be used in organic light-emitting devices (OLEDs) for device elements capable of emitting light of color ranging from orange to red with high-efficiency and high-brightness. wherein E=Group 16 elements (including sulphur); M=Group 10 metal (including platinum); R1-R14 are each independently selected from the group consisting of hydrogen; halogen; alkyl; substituted alkyl; aryl; substituted aryl, with substituents selected from the group consisting of halogen, lower alkyl and recognized donor and acceptor groups. R1 can also be selected from (C?C)nR15, where (C?C) represents a carbon-carbon triple bond (acetylide group), n is selected from 1 to 10, and R15 is selected from alkyl, aryl, substituted aryl, and tri(alkyl)silyl.

Abstract: Disclosed are electrophosphorescent organic metal complexes with formula (I) or (II), of either geometrical isomers, comprising two bidentate NN-type ligandsor a tetradentate NNNN-type ligand, and a transition metal. These electrophosphorescent materials are valuable to the application in organic light-emitting devices (OLEDs), including red-, orange-, or yellow-light OLEDs.

Abstract: The present invention relates to lanthanide porphyrin complexes and their uses as anti-tumor agents. The described complexes show promising cytotoxic properties toward cancer cells in both in vitro and in vivo studies.

Abstract: The present invention relates to a pharmaceutical composition comprising one or more of the following ruthenium oxalato compounds I, II, III and IV as an active ingredient. The pharmaceutical composition can be used for the treatment of viral-infected patients or prophylactic treatment of patients at risk from viral infection.

Abstract: Gold(III) phosphine complexes [Aum(CNC)mL]n+ (where HCNCH=2,6-diphenylpyridine) and their use as anti-tumor agents are disclosed. Notable results for the appearance of new potential anti-tumor application of these gold(III) complexes are reported. The described complexes show promising cytotoxic properties toward cancer cells in both in vitro and in vivo studies.